Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN null / Valor 1720684

NASDAQ (2026-08-28)
USD 218.50-1.35%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

64.7%1Y
-17.6%3Y
-36.3%5Y

Performance

35.2%1Y
30.4%3Y
33.3%5Y

Volatility

Market cap

32284 M

Market cap (USD)

Daily traded volume (Shares)

517,485

Daily traded volume (Shares)

1 day high/low

151.14 / 148.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

agilon health inc
agilon health inc agilon health inc Valor: 110653729
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.74%USD 92.54
Laurus Labs Ltd.
Laurus Labs Ltd. Laurus Labs Ltd. Valor: 56464789
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.80%INR 1,935.30
Healthcare Services Group Inc
Healthcare Services Group Inc Healthcare Services Group Inc Valor: 938239
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.18%USD 22.44
GE Healthcare Technologies Inc
GE Healthcare Technologies Inc GE Healthcare Technologies Inc Valor: 123735674
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.04%USD 71.72
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.23%USD 237.10
Arvinas Inc
Arvinas Inc Arvinas Inc Valor: 43526042
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.65%USD 9.18
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc Ironwood Pharmaceuticals Inc Valor: 10773079
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.59%USD 4.13
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.76%USD 56.28
Baxter International Inc
Baxter International Inc Baxter International Inc Valor: 911702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.77%USD 26.13
Cardinal Health Inc
Cardinal Health Inc Cardinal Health Inc Valor: 196652
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.25%USD 234.55